LON:MXCT MaxCyte (MXCT) Share Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free MXCT Stock Alerts GBX 295 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range 290▼ 30050-Day Range 295▼ 37552-Week Range 180▼ 430Volume5,668 shsAverage Volume32,593 shsMarket Capitalization£307.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get MaxCyte alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About MaxCyte Stock (LON:MXCT)MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Read More MXCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MXCT Stock News HeadlinesApril 3, 2024 | insidertrades.comMaxCyte, Inc. (LON:MXCT) Insider Sells £22,050 in StockApril 19, 2024 | americanbankingnews.comMaxCyte (LON:MXCT) Stock Price Crosses Below 50 Day Moving Average of $344.50April 26, 2024 | DTI (Ad)My top 100 stocks…We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well.April 4, 2024 | finance.yahoo.comNotice of Annual General Meeting of Vicore Pharma Holding AB (publ)March 14, 2024 | finance.yahoo.comMaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | finance.yahoo.comMaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five yearsMarch 12, 2024 | finance.yahoo.comMaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023March 11, 2024 | markets.businessinsider.comMaxCyte earnings: here's what Wall Street expectsApril 26, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. March 11, 2024 | benzinga.comMaxCyte Earnings PreviewJanuary 27, 2024 | msn.comMaxCyte Inc Announces Cenk Sumen’s Transition and Severance TermsJanuary 9, 2024 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial ResultsJanuary 8, 2024 | msn.comMaxCyte says Q4 revenue is expected to be between $15.5M and $15.7MJanuary 8, 2024 | finance.yahoo.comMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial ResultsJanuary 3, 2024 | msn.comMaxCyte and Lion TCR join hands for Lion TCR's global expansionDecember 12, 2023 | bizjournals.comLongtime MaxCyte CEO Doug Doerfler to retire; Maher Masoud tapped as successorDecember 2, 2023 | finance.yahoo.comInsider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT)November 27, 2023 | seekingalpha.comMaxCyte May Benefit From Potential Gene Therapy ApprovalNovember 16, 2023 | finance.yahoo.comMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding MemberNovember 15, 2023 | finance.yahoo.comMaxCyte, Inc. (LON:MXCT) Analysts Just Cut Their EPS Forecasts SubstantiallyNovember 9, 2023 | finance.yahoo.comMaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | finance.yahoo.comMaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue GuidanceNovember 6, 2023 | finance.yahoo.comMaxCyte to Participate in Two Upcoming Investor ConferencesOctober 23, 2023 | finance.yahoo.comOne MaxCyte Insider Raised Stake By 400% In Previous YearOctober 7, 2023 | finance.yahoo.comNeed To Know: The Consensus Just Cut Its MaxCyte, Inc. (LON:MXCT) Estimates For 2023October 4, 2023 | ca.investing.comAfter-hours movers: Clorox falls on Q1 warning, BlackBerry up on split-off plansOctober 4, 2023 | finance.yahoo.comMaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue GuidanceSee More Headlines Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolLON:MXCT CUSIPN/A CIKN/A Webwww.maxcyte.com Phone+1-301-9441700FaxN/AEmployees143Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-37,920,000.00 Net Margins-91.85% Pretax MarginN/A Return on Equity-15.60% Return on Assets-10.88% Debt Debt-to-Equity Ratio8.07 Current Ratio10.65 Quick Ratio14.38 Sales & Book Value Annual Sales£41.29 million Price / Sales7.52 Cash FlowGBX 151.12 per share Price / Cash Flow1.97 Book ValueGBX 223 per share Price / Book1.34Miscellaneous Outstanding Shares104,130,000Free FloatN/AMarket Cap£310.31 million OptionableNot Optionable Beta1.04 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Maher Masoud (Age 48)President, CEO, Secretary & Director Comp: $484.7kMr. Douglas Arthur Doerfler (Age 68)Founder Comp: $950.01kMr. Douglas J. Swirsky CFA (Age 55)CPA, Chief Financial Officer Mr. Jay GelfmanSenior Vice President of OperationsMr. Ronald Evan Holtz CPA (Age 66)Ph.D., Executive Vice President of Administration Comp: $514.26kMr. Sean MenarguezDirector of Investor RelationsMr. David SandovalSenior Vice President & General CounselMr. Thomas Michael Ross (Age 63)Executive Vice President of Global Sales Mr. Jack HorganVice President of Corporate DevelopmentMs. Jill MayerSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsNIOX GroupLON:NIOXCreo Medical GroupLON:CREOEKF DiagnosticsLON:EKFBenchmarkLON:BMKHorizon Discovery Group plc (HZD.L)LON:HZDView All CompetitorsInsidersJohn JohnstonSold 5,000 sharesTotal: £2.21 M ($441.00/share)John JohnstonSold 200 sharesTotal: £90,600.00 ($453.00/share)John JohnstonSold 118 sharesTotal: £56,640.00 ($480.00/share)Doug DoerflerSold 28,883 sharesTotal: £14.56 M ($504.00/share)View All Insider Transactions MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed in 2024? MaxCyte's stock was trading at GBX 352.50 at the beginning of the year. Since then, MXCT shares have decreased by 16.3% and is now trading at GBX 295. View the best growth stocks for 2024 here. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), Astrotech (ASTC), Arcturus Therapeutics (ARCT), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC). How do I buy shares of MaxCyte? Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:MXCT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsBiden out June 13; Kamala won’t replace him?Paradigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
